Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2022-05, Vol.167, p.149-151 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 151 |
|---|---|
| container_issue | |
| container_start_page | 149 |
| container_title | European journal of cancer (1990) |
| container_volume | 167 |
| creator | De Ruysscher, Dirk Remon, Jordi Hendriks, Lizza E.L. |
| description | |
| doi_str_mv | 10.1016/j.ejca.2022.02.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2641512236</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804922001071</els_id><sourcerecordid>2672767083</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-be2ff86ab568bd1b168ae0d5762bea6eb3d9846fd20a95041b4111149c813a823</originalsourceid><addsrcrecordid>eNp9kM9rFTEQx4Mo9ln9BzxIwEsv-5xkN9ksCCKl6oNCD1U8hvyYrVl2k5rsFvzvzeNVDx4chpnLZ74MH0JeM9gzYPLdtMfJmT0HzvdQm4knZMdUPzSgBH9KdjCIoVHQDWfkRSkTAPSqg-fkrBUt9FyIHbn9_iNRixHHsBY65rRQl2JJc_BmDSlSv-UHM2-LsTREWlZzh_RwONCYYlMWM8_UYR3zFu-oM9Fh_vCSPBvNXPDV4z4n3z5dfb380lzffD5cfrxuXKu6tbHIx1FJY4VU1jPLpDIIXvSSWzQSbesH1cnRczCDgI7ZjtXqBqdYaxRvz8nFKfc-p58bllUvoRy_MRHTVjSXHROM81ZW9O0_6JS2HOt3lep5L3tQbaX4iXI5lZJx1Pc5LCb_0gz0Ubme9FG5PirXUJuJevTmMXqzC_q_J38cV-D9CcDq4iFg1sUFrKZ8yOhW7VP4X_5vQ7aQow</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2672767083</pqid></control><display><type>article</type><title>Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>De Ruysscher, Dirk ; Remon, Jordi ; Hendriks, Lizza E.L.</creator><creatorcontrib>De Ruysscher, Dirk ; Remon, Jordi ; Hendriks, Lizza E.L.</creatorcontrib><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2022.02.015</identifier><identifier>PMID: 35307255</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Chemoradiotherapy ; Humans ; Immunotherapy ; Lung cancer ; Lung Neoplasms - drug therapy ; Monoclonal antibodies ; Non-small cell lung carcinoma ; Small cell lung carcinoma ; Targeted cancer therapy</subject><ispartof>European journal of cancer (1990), 2022-05, Vol.167, p.149-151</ispartof><rights>2022 Elsevier Ltd</rights><rights>Copyright Elsevier Science Ltd. May 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-be2ff86ab568bd1b168ae0d5762bea6eb3d9846fd20a95041b4111149c813a823</citedby><cites>FETCH-LOGICAL-c384t-be2ff86ab568bd1b168ae0d5762bea6eb3d9846fd20a95041b4111149c813a823</cites><orcidid>0000-0002-3521-2535 ; 0000-0002-9462-875X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0959804922001071$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35307255$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Ruysscher, Dirk</creatorcontrib><creatorcontrib>Remon, Jordi</creatorcontrib><creatorcontrib>Hendriks, Lizza E.L.</creatorcontrib><title>Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Chemoradiotherapy</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Monoclonal antibodies</subject><subject>Non-small cell lung carcinoma</subject><subject>Small cell lung carcinoma</subject><subject>Targeted cancer therapy</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM9rFTEQx4Mo9ln9BzxIwEsv-5xkN9ksCCKl6oNCD1U8hvyYrVl2k5rsFvzvzeNVDx4chpnLZ74MH0JeM9gzYPLdtMfJmT0HzvdQm4knZMdUPzSgBH9KdjCIoVHQDWfkRSkTAPSqg-fkrBUt9FyIHbn9_iNRixHHsBY65rRQl2JJc_BmDSlSv-UHM2-LsTREWlZzh_RwONCYYlMWM8_UYR3zFu-oM9Fh_vCSPBvNXPDV4z4n3z5dfb380lzffD5cfrxuXKu6tbHIx1FJY4VU1jPLpDIIXvSSWzQSbesH1cnRczCDgI7ZjtXqBqdYaxRvz8nFKfc-p58bllUvoRy_MRHTVjSXHROM81ZW9O0_6JS2HOt3lep5L3tQbaX4iXI5lZJx1Pc5LCb_0gz0Ubme9FG5PirXUJuJevTmMXqzC_q_J38cV-D9CcDq4iFg1sUFrKZ8yOhW7VP4X_5vQ7aQow</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>De Ruysscher, Dirk</creator><creator>Remon, Jordi</creator><creator>Hendriks, Lizza E.L.</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3521-2535</orcidid><orcidid>https://orcid.org/0000-0002-9462-875X</orcidid></search><sort><creationdate>202205</creationdate><title>Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?</title><author>De Ruysscher, Dirk ; Remon, Jordi ; Hendriks, Lizza E.L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-be2ff86ab568bd1b168ae0d5762bea6eb3d9846fd20a95041b4111149c813a823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Chemoradiotherapy</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Monoclonal antibodies</topic><topic>Non-small cell lung carcinoma</topic><topic>Small cell lung carcinoma</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Ruysscher, Dirk</creatorcontrib><creatorcontrib>Remon, Jordi</creatorcontrib><creatorcontrib>Hendriks, Lizza E.L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Ruysscher, Dirk</au><au>Remon, Jordi</au><au>Hendriks, Lizza E.L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2022-05</date><risdate>2022</risdate><volume>167</volume><spage>149</spage><epage>151</epage><pages>149-151</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>35307255</pmid><doi>10.1016/j.ejca.2022.02.015</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-3521-2535</orcidid><orcidid>https://orcid.org/0000-0002-9462-875X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2022-05, Vol.167, p.149-151 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2641512236 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antibodies, Monoclonal - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Chemoradiotherapy Humans Immunotherapy Lung cancer Lung Neoplasms - drug therapy Monoclonal antibodies Non-small cell lung carcinoma Small cell lung carcinoma Targeted cancer therapy |
| title | Who benefits from consolidation durvalumab in stage III non-small cell lung cancer? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A57%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Who%20benefits%20from%20consolidation%20durvalumab%20in%20stage%20III%20non-small%20cell%20lung%20cancer?&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=De%20Ruysscher,%20Dirk&rft.date=2022-05&rft.volume=167&rft.spage=149&rft.epage=151&rft.pages=149-151&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2022.02.015&rft_dat=%3Cproquest_cross%3E2672767083%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2672767083&rft_id=info:pmid/35307255&rft_els_id=S0959804922001071&rfr_iscdi=true |